[go: up one dir, main page]

SI3341015T2 - Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist - Google Patents

Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Info

Publication number
SI3341015T2
SI3341015T2 SI201631329T SI201631329T SI3341015T2 SI 3341015 T2 SI3341015 T2 SI 3341015T2 SI 201631329 T SI201631329 T SI 201631329T SI 201631329 T SI201631329 T SI 201631329T SI 3341015 T2 SI3341015 T2 SI 3341015T2
Authority
SI
Slovenia
Prior art keywords
blockade
targeted cells
immune costimulatory
enhanced depletion
costimulatory agonist
Prior art date
Application number
SI201631329T
Other languages
Slovenian (sl)
Other versions
SI3341015T1 (en
Inventor
Peter Schnorr
Akanksha Chhabra
Judith A. Shizuru
Irving L. Weissman
Kipp Andrew Weiskopf
Original Assignee
The Board Of Trustees Of The Leland Stanford, Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3341015(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford, Junior University filed Critical The Board Of Trustees Of The Leland Stanford, Junior University
Publication of SI3341015T1 publication Critical patent/SI3341015T1/en
Publication of SI3341015T2 publication Critical patent/SI3341015T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201631329T 2015-08-26 2016-08-26 Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist SI3341015T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210279P 2015-08-26 2015-08-26
EP16840215.4A EP3341015B2 (en) 2015-08-26 2016-08-26 Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
PCT/US2016/049016 WO2017035480A1 (en) 2015-08-26 2016-08-26 Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Publications (2)

Publication Number Publication Date
SI3341015T1 SI3341015T1 (en) 2021-11-30
SI3341015T2 true SI3341015T2 (en) 2024-03-29

Family

ID=58100930

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631329T SI3341015T2 (en) 2015-08-26 2016-08-26 Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Country Status (10)

Country Link
US (4) US10894831B2 (en)
EP (1) EP3341015B2 (en)
JP (3) JP7198083B2 (en)
AU (2) AU2016310348B2 (en)
CA (1) CA2996167A1 (en)
ES (1) ES2894335T5 (en)
PL (1) PL3341015T5 (en)
PT (1) PT3341015T (en)
SI (1) SI3341015T2 (en)
WO (1) WO2017035480A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
WO2016065245A1 (en) * 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
JP7198083B2 (en) 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Enhanced depletion of target cells using CD47 blockade and immune co-stimulatory agonists
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
KR102776457B1 (en) 2017-10-18 2025-03-06 포티 세븐, 엘엘씨 Anti-CD47 agonist-based ovarian cancer therapy
PE20201265A1 (en) 2018-03-21 2020-11-19 Alx Oncology Inc ANTIBODIES AGAINST SIGNAL REGULATORY ALPHA PROTEIN AND METHODS OF USE
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (en) 2018-09-27 2021-06-29 Celgene Corporation Sirpa binding proteins and methods of using them
US20220119523A1 (en) * 2019-02-08 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
PE20230160A1 (en) 2019-12-17 2023-02-01 Pfizer SPECIFIC ANTIBODIES FOR CD47, PD-L1 AND THEIR USES
JP2024520902A (en) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド Combination Therapies for Treating Cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245752A1 (en) 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
KR20110085038A (en) 2010-01-19 2011-07-27 울산대학교 산학협력단 Removal of CD137 positive cells using anti-CD137-antibody and toxin conjugate
HRP20170254T1 (en) 2010-05-14 2017-04-21 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel CD47 humanized and chimeric monoclonal antibodies
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
MX2015007446A (en) 2012-12-12 2015-12-07 Vasculox Inc Therapeutic cd47 antibodies.
EP3066127A1 (en) * 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2728668T3 (en) * 2014-01-08 2019-10-28 Univ Leland Stanford Junior Targeted therapy for small cell lung cancer
CN113621075B (en) 2014-08-08 2024-09-20 Alx肿瘤生物技术公司 SIRP-alpha variant constructs and uses thereof
ES2945588T3 (en) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Stem cell engraftment with a combination of a stem cell-targeted agent and modulation of immunoregulatory signaling
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
JP6898303B2 (en) 2015-08-07 2021-07-07 エーエルエックス オンコロジー インコーポレイテッド SIRP-Structures with alpha domain or variants thereof
JP7198083B2 (en) * 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Enhanced depletion of target cells using CD47 blockade and immune co-stimulatory agonists
CN108367073A (en) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 Treating cancer with dual targeting of CD47 and EGFR

Also Published As

Publication number Publication date
US20210095034A1 (en) 2021-04-01
JP7313398B2 (en) 2023-07-24
AU2016310348A1 (en) 2018-03-15
EP3341015A4 (en) 2018-07-11
US12030944B2 (en) 2024-07-09
HK1257824A1 (en) 2019-11-01
US20230257464A1 (en) 2023-08-17
EP3341015A1 (en) 2018-07-04
CA2996167A1 (en) 2017-03-02
US11608377B2 (en) 2023-03-21
PL3341015T5 (en) 2024-04-08
PT3341015T (en) 2021-10-12
SI3341015T1 (en) 2021-11-30
ES2894335T5 (en) 2024-06-27
AU2016310348B2 (en) 2023-01-05
PL3341015T3 (en) 2021-12-13
JP7198083B2 (en) 2022-12-28
WO2017035480A1 (en) 2017-03-02
JP2023126368A (en) 2023-09-07
US10894831B2 (en) 2021-01-19
JP2018525421A (en) 2018-09-06
AU2023201987A1 (en) 2023-05-04
US20200223923A1 (en) 2020-07-16
EP3341015B2 (en) 2023-12-27
US20240400688A1 (en) 2024-12-05
JP2021138756A (en) 2021-09-16
EP3341015B1 (en) 2021-07-28
ES2894335T3 (en) 2022-02-14

Similar Documents

Publication Publication Date Title
PL3341015T5 (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
IL304117A (en) Anti-pvrig antibodies and methods of use
IL257636A (en) Anti-tigit antibodies and methods of use
ZA201707550B (en) Methods of increasing strength and functionality with gdf8 inhibitors
IL254458A0 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
SG10202110908WA (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
ZA201801048B (en) Encoderless motor with improved granularity and methods of use
EP3075001A4 (en) Detectors and methods of using them
ZA201801548B (en) Cyano thienotriazolodiazepines and uses thereof
IL254412A0 (en) Prostate antigen standards and uses thereof
GB2534557B (en) Methods and resources for creating permissions